SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Qualified Opinion who wrote (3044)8/13/2002 10:14:28 PM
From: William Partmann  Read Replies (2) of 10345
 
<<Some physicians have predicted that Myobloc is going to be more expensive than Botox because it does not last as long. Others say they welcome the Myobloc alternative because they believe Elan will have to price their product competitively, and the end result is likely to be a lower price for both products.>>

Thanks for the post. Low margins on a product is a great way to make money. A great board of directors but wait, the company has multiple CEOs on the payroll. Woow, they are way ahead of the curve. Not to mention a clear roadmap for the future. Oh, and don't forget Skelaxin! Is this a great company or what?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News